Alpha 2.0
Login Register
» Articles » PMID: 6234858

Cross-resistance Among Cinoxacin, Ciprofloxacin, DJ-6783, Enoxacin, Nalidixic Acid, Norfloxacin, and Oxolinic Acid After in Vitro Selection of Resistant Populations

Overview
Journal Antimicrob Agents Chemother
Publisher American Society for Microbiology
Specialty Pharmacology
Date 1984 Jun 1
PMID 6234858
Citations 39
Authors
A L Barry
R N Jones
Affiliations
Soon will be listed here.
Abstract

Six different gram-negative bacilli were serially transferred through subinhibitory concentrations of seven quinolone derivatives or related organic acids. A gradual, stepwise decrease in susceptibility was noted with all seven drugs, and the resistant cultures demonstrated a concomitant cross-resistance to the other drugs.

Citing Articles

Maximum levels of cross-contamination for 24 antimicrobial active substances in non-target feed.
Part 10: .

Koutsoumanis K, Allende A, Alvarez-Ordonez A, Bolton D, Bover-Cid S, Chemaly M EFSA J. 2021; 19(10):e06862.

PMID: 34729090 PMC: 8546796. DOI: 10.2903/j.efsa.2021.6862.

Bacterial antibiotic resistance development and mutagenesis following exposure to subinhibitory concentrations of fluoroquinolones : a systematic review of the literature.

Ching C, Orubu E, Sutradhar I, Wirtz V, Boucher H, Zaman M JAC Antimicrob Resist. 2021; 2(3):dlaa068.

PMID: 34223024 PMC: 8210091. DOI: 10.1093/jacamr/dlaa068.

Development and selection of low-level multi-drug resistance over an extended range of sub-inhibitory ciprofloxacin concentrations in Escherichia coli.

Ching C, Zaman M Sci Rep. 2020; 10(1):8754.

PMID: 32471975 PMC: 7260183. DOI: 10.1038/s41598-020-65602-z.

Control of fluoroquinolone resistance through successful regulation, Australia.

Cheng A, Turnidge J, Collignon P, Looke D, Barton M, Gottlieb T Emerg Infect Dis. 2012; 18(9):1453-60.

PMID: 22932272 PMC: 3437704. DOI: 10.3201/eid1809.111515.

Enoxacin: a reappraisal of its clinical efficacy in the treatment of genitourinary tract infections.

Patel S, Spencer C Drugs. 1996; 51(1):137-60.

PMID: 8741236 DOI: 10.2165/00003495-199651010-00009.

References
1.
Ronald A, Turck M, Petersdorf R . A critical evaluation of nalidixic acid in urinary-tract infections. N Engl J Med. 1966; 275(20):1081-9. DOI: 10.1056/NEJM196611172752001. View
2.
Lumish R, NORDEN C . Cinoxacin: in vitro antibacterial studies of a new synthetic organic acid. Antimicrob Agents Chemother. 1975; 7(2):159-63. PMC: 429096. DOI: 10.1128/AAC.7.2.159. View
3.
Gellert M, Mizuuchi K, ODea M, Itoh T, TOMIZAWA J . Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity. Proc Natl Acad Sci U S A. 1977; 74(11):4772-6. PMC: 432037. DOI: 10.1073/pnas.74.11.4772. View
4.
Neu H, Labthavikul P . In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim. Antimicrob Agents Chemother. 1982; 22(1):23-7. PMC: 183667. DOI: 10.1128/AAC.22.1.23. View
5.
Tenney J, Maack R, Chippendale G . Rapid selection of organisms with increasing resistance on subinhibitory concentrations of norfloxacin in agar. Antimicrob Agents Chemother. 1983; 23(1):188-9. PMC: 184643. DOI: 10.1128/AAC.23.1.188. View